GlassScriptPhysician profile
Yadira Hernandez
NPI 1538272521
$2,036.96
in general payments reported to CMS, 2019-2025
20 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $230 · 2021: $441 · 2022: $210 · 2023: $129 · 2024: $587 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $366.90 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $252.82 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $191.22 | 2020-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $190.72 | 2020-2025 | Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $181.81 | 2023-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $145.85 | 2020-2025 | Invega Sustenna, Spravato |
| Bausch Health US, LLC | $101.99 | 2024-2025 | Aplenzin |
| Tris Pharma INC | $87.11 | 2021-2025 | Dyanavel Xr |
| Corium, LLC | $82.94 | 2022-2025 | Azstarys |
| Allergan, INC. | $82.41 | 2020 | |
| Axsome Therapeutics, INC. | $63.25 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $58.85 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $52.02 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $37.80 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $33.99 | 2025 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.18 | 2021 | |
| Neurocrine Biosciences, INC. | $21.75 | 2025 | |
| Vanda Pharmaceuticals INC. | $20.81 | 2025 | Fanapt |
| Vertical Pharmaceuticals, LLC | $20.25 | 2024 | Relexxii |
| Adlon Therapeutics L.P. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yadira Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.